ClinicalTrials.gg
CompletedNCT02707601Co-STARsUpdated Nov 14, 2018Results posted

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

A Phase 3 interventional study of E/C/F/TAF and F/R/TAF in HIV-1 Infection and HCV Infection, sponsored by Gilead Sciences. Completed at 43 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies in Hepatitis C by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Hepatitis C · Gilead Sciences.

Enrollment
39th of 97
150 · median 111
Started
2016
with 12 others
Phase 3
35 of 110
none open now
Registered
91st of 110
by date

Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 39th largest by enrollment of the 97 interventional ones that give a count, is one of 13 that started in 2016, is one of 35 in phase 3, and was the 91st registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 110 studies in Hepatitis C by Gilead Sciences is open now. The open studies under Hepatitis C, anywhere →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 110 studies in Hepatitis C by Gilead Sciences as a file.
02

Study summary

This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or emtricitabine/rilpivirine/tenofovir alafenamide (F/R/TAF) from the current antiretroviral (ARV) therapy and in virologically-suppressed, HIV-1/HCV co-infected participants.

03

Conditions studied

  • HIV-1 Infection
  • HCV Infection

Browse trials for

Keywords

  • HIV
  • HCV
  • Antiretroviral therapy
  • HCV direct acting antiviral(s) (DAA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Chronic genotype (GT) 1, infected, male and non-pregnant/ non-lactating female individuals, without cirrhosis, treatment-naive or treatment-experienced with interferon (IFN) +/- ribavirin (RBV) +/- HCV protease inhibitor (PI).
  • Compensated cirrhotic individuals must be HCV treatment-naive.
  • No prior treatments with NS5A and NS5B or any HCV direct acting antivirals, except boceprevir, telaprevir and simeprevir, in combination with IFN and RBV
  • Currently on an ARV regimen (2 NRTI + a third agent) without change for 6 months prior to screening.
  • Documented plasma -1 RNA levels \< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) for ≥ 6 months preceding the screening visit. After reaching HIV-1 RNA \< 50 copies/mL, single values ("blips") of HIV-1 RNA ≥ 50 copies/mL followed by resuppression is allowed.
  • For individuals with 3 or more prior ARV regimens, a regimen history should be provided for approval by the Sponsor.

    • Note: Individuals that changed from TDF to TAF less than 6 months ago will be eligible as long as the TDF/ TAF change was the only change to the regimen.
  • Plasma HIV-1 RNA level \< 50 copies/mL at the screening visit
  • Have no documented resistance to any of the HIV study agents at time in the past, including but not limited to the reverse transcriptase resistance mutations K65R, K70E, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C, M230I/L, the combination of K103N+L100I, or 3 or more thymidine analog associated mutations (TAMs) that include M41L or L210W (TAMs are M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R). If a historical genotype prior to first ARV is not available or individual had 3 or more prior ARV regimens, individual will have proviral genotype analysis for archived resistance prior to Day 1.
  • No history of HIV virologic failure
  • No evidence of infection
  • Estimated (eGFR) ≥ 30 mL/min as estimated by formula

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF + LDV/SOF

    Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF. Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA \< 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study.

    Drug: E/C/F/TAF · Drug: LDV/SOF

  • Experimental
    F/R/TAF + LDV/SOF

    Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF. Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA \< 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study.

    Drug: F/R/TAF · Drug: LDV/SOF

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)

    Sustained Virologic Response (SVR12) was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment.

    Time frame: HCV Posttreatment Week 12

Secondary outcomes

  1. Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)

    SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping LDV/SOF treatment.

    Time frame: HCV Posttreatment Week 4

  2. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: 24 weeks after start of HIV treatment

  3. Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment

    Time frame: Up to 32 weeks plus 30 days

07

Results

Posted Oct 9, 2018

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 01 April 2016. The last study visit occurred on 29 September 2017.

Participant flow — Overall Study
MilestoneE/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOF
Started7674
Completed7270
Not completed44
Withdrew: Death01
Withdrew: Lack of efficacy01
Withdrew: Investigator's discretion10
Withdrew: Withdrew consent01
Withdrew: Lost to follow-up11
Withdrew: Participants randomized but not treated20

Outcome measures

PrimaryPercentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)

Sustained Virologic Response (SVR12) was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment.

Time frame:
HCV Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)
percentage of participantsE/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOF
Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)98.6 (92.5 to 100.0)95.8 (88.3 to 99.1)
Statistical analysis
  • E/C/F/TAF + LDV/SOF · Binomial test · p = 0.002 (The p-value is obtained from the 2-sided exact 1-sample binomial test for the superiority over the performance goal of 88%.)
  • F/R/TAF + LDV/SOF · Binomial test · p = 0.042 (The p-value is obtained from the 2-sided exact 1-sample binomial test for the superiority over the performance goal of 88%.)
SecondaryPercentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)

SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping LDV/SOF treatment.

Time frame:
HCV Posttreatment Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)
percentage of participantsE/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOF
Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)98.6 (92.5 to 100.0)98.6 (92.5 to 100.0)
Statistical analysis
  • E/C/F/TAF + LDV/SOF · Binomial test · p = 0.002 (The p-value is obtained from the 2-sided exact 1-sample binomial test for the superiority over the performance goal of 88%.)
  • F/R/TAF + LDV/SOF · Binomial test · p = 0.002 (The p-value is obtained from the 2-sided exact 1-sample binomial test for the superiority over the performance goal of 88%.)
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
24 weeks after start of HIV treatment
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm
percentage of participantsE/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOF
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm1.41.4
Statistical analysis
  • E/C/F/TAF + LDV/SOF vs F/R/TAF + LDV/SOF · Fisher exact test · p = 1.00 · Difference in percentages: 0.0 · 95% CI -6.1 to 6.1The differences in percentages of participants between treatment groups and their 95% confidence intervals (CIs) were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment
Time frame:
Up to 32 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment
percentage of participantsE/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20)F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20)E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12)F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12)
Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment62.569.483.879.7

Adverse events

Collected over Up to 32 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E/C/F/TAF + LDV/SOF0/74 (0%)7/74 (9.5%)46/74 (62.2%)
F/R/TAF + LDV/SOF1/74 (1.4%)12/74 (16.2%)36/74 (48.6%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventE/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOF
PneumoniaInfections and infestations0/742/74
Iron deficiency anaemiaBlood and lymphatic system disorders1/740/74
Abdominal painGastrointestinal disorders0/741/74
AstheniaGeneral disorders0/741/74
Chest painGeneral disorders0/741/74
GastroenteritisInfections and infestations1/740/74
InfluenzaInfections and infestations0/741/74
Testicular abscessInfections and infestations0/741/74
Tooth infectionInfections and infestations1/740/74
Ankle fractureInjury, poisoning and procedural complications0/741/74
Most frequent other events
Showing 10 of 16
Most frequent other events
EventE/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOF
Urinary tract infectionInfections and infestations10/742/74
CoughRespiratory, thoracic and mediastinal disorders6/7410/74
Upper respiratory tract infectionInfections and infestations9/745/74
HeadacheNervous system disorders3/748/74
ArthralgiaMusculoskeletal and connective tissue disorders7/745/74
DiarrhoeaGastrointestinal disorders6/743/74
NauseaGastrointestinal disorders4/746/74
Pain in extremityMusculoskeletal and connective tissue disorders6/741/74
FatigueGeneral disorders4/745/74
Vitamin D deficiencyMetabolism and nutrition disorders5/742/74

Baseline characteristics

Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug (E/C/F/TAF, F/R/TAF, or LDV/SOF).

Age, Continuous
Age, Continuous(years)E/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOFTotal
Mean51 ± 9.552 ± 9.951 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOFTotal
Female162238
Male5852110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)E/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOFTotal
Hispanic or Latino131427
Not Hispanic or Latino6159120
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOFTotal
Asian101
Black303161
White413778
Native Hawaiian or Pacific Islander022
Other235
American Indian or Alaska Native011
HCV RNA Category
HCV RNA Category(Participants)E/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOFTotal
< 800,000 IU/mL251439
≥ 800,000 IU/mL4960109
HIV-1 RNA Category
HIV-1 RNA Category(Participants)E/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOFTotal
< 50 copies/mL7374147
≥ 50 copies/mL101
HCV RNA
HCV RNA(log10 IU/mL)E/C/F/TAF + LDV/SOFF/R/TAF + LDV/SOFTotal
Mean6.0 ± 1.076.3 ± 0.746.2 ± 0.92
08

Study locations

43 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama, United States
  • Spectrum Medical Group
    Phoenix, Arizona, United States
  • Mills Clinical Research
    Los Angeles, California, United States
  • Peter J Ruane MD Inc
    Los Angeles, California, United States
  • University of California Davis
    Sacramento, California, United States
  • University of California San Diego
    San Diego, California, United States
  • Kaiser Permanente
    San Francisco, California, United States
  • The George Washington University Medical Center
    Washington, District of Columbia, United States
  • Whitman-Walker Health
    Washington, District of Columbia, United States
  • Community AIDS Network
    Clearwater, Florida, United States
  • Gary Richmond, MD, PA, Inc.
    Fort Lauderdale, Florida, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida, United States
  • Midway Immunology & Research Center, LLC
    Fort Pierce, Florida, United States
  • AIDS Healthcare Foundation
    Miami Beach, Florida, United States
  • University of Miami
    Miami, Florida 33136, United States
  • AIDS Healthcare Foundation
    Miami, Florida, United States
  • Orlando Immunology Center
    Orlando, Florida, United States
  • St. Josephs Comprehensive Research Institute
    Tampa, Florida, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida, United States
  • Rowan Tree Medical PA
    Wilton Manors, Florida, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia, United States
  • Emory University
    Atlanta, Georgia, United States
  • Chatham County Health Department
    Savannah, Georgia, United States
  • The CORE Foundation
    Chicago, Illinois, United States
  • Be Well Medical Center
    Berkley, Michigan, United States
  • Kansas City Free Health Clinic
    Kansas City, Missouri, United States
  • Saint Michael's Medical Center
    Newark, New Jersey, United States
  • Weill Cornell Medical College
    New York, New York, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina, United States
  • Duke University
    Durham, North Carolina, United States
  • East Carolina University
    Greenville, North Carolina, United States
  • Lehigh Valley Health Network, Network Office of Research and Innovation
    Allentown, Pennsylvania, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
  • Central Texas Clinical Research
    Austin, Texas, United States
  • UT Southwestern Medical Center
    Dallas, Texas, United States
  • Gordon E. Crofoot MD PA
    Houston, Texas, United States
  • Therapeutics Concepts, PA
    Houston, Texas, United States
  • Clinical Alliance for Research & Education
    Annandale, Virginia, United States
  • Peter Shalit MD
    Seattle, Washington, United States
  • Southern Cal
    Spokane, Washington, United States
  • Community Health Care
    Tacoma, Washington, United States
  • Clinical Research Puerto Rico Inc
    San Juan, Puerto Rico
09

References and documents

Publications

  • Ramgopal M, Jain M, Hinestrosa F, Asmuth D, Huhn G, Slim J, et al. HIV-1/HCV Coinfection Treatment with Single-Tablet Antiviral Regimens (CoSTARs): 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) after Randomized Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Rilpivirine/F/TAF (R/F/TAF) [Poster LB-12]. AASLD: The Liver Meeting 2017 20-24 October; Washington DC.
  • Huhn G, Jain M, Hinestrosa F, Asmuth D, Huhn G, Slim J, et al. HIV-1/HCV Coinfection Treatment with Single-Tablet Antiviral Regimens (CoSTARs): 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) after Randomized Switch to Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Rilpivirine/F/TAF (R/F/TAF) [Poster PE16/52]. European AIDS Conference 2017 25-27 October; Milan Italy.
  • Huhn GD, Ramgopal M, Jain MK, Hinestrosa F, Asmuth DM, Slim J, Goldstein D, Applin S, Ryu JH, Jiang S, Cox S, Das M, Nguyen-Cleary T, Piontkowsky D, Guyer B, Rossaro L, Haubrich RH. HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS One. 2020 Jan 29;15(1):e0224875. doi: 10.1371/journal.pone.0224875. eCollection 2020. PubMed 31995556 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Sep 2017, 17 months.

Results were first posted in Oct 2018, 1 year after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 17 months is above that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2016
First posted
Mar 14, 2016
StartActual
Apr 1, 2016
Primary completionActual
Sep 14, 2017
CompletionActual
Sep 29, 2017
Results first posted
Oct 9, 2018
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02707601
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 14, 2016
Start date
Apr 1, 2016
Primary completion
Sep 14, 2017
Completion
Sep 29, 2017
Results posted
Oct 9, 2018
Last update
Nov 14, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate

Start the discussion